Resilient Biopharma Leadership With Ambrx's Dan O'Connor
Business Of Biotech
00:00
The Importance of Fear in a Business
Dan O'Connor: I think we have not only the HER2 program, but the prostate program that we have is heating up really nicely. It's super interesting because people have tried to target this particular target. We're having an opposite because the strength of our conjugation isn't full toxicity. And I think we're going to be able to get to a therapeutic dose for Urbatex. Matt Piller: This biotech podcast is produced by bio process online with a support of Saitiva BioPharma.
Transcript
Play full episode
